文献速递疼痛医学

个体阿片类药物对慢性非癌痛的比较获益与危害:随机试验的系统综述与网络荟萃分析

Comparative benefits and harms of individual opioids for chronic non-cancer pain: a systematic review and network meta-analysis of randomised trials.
PubMed 文献 · Br J Anaesth · 2022-07-09

与安慰剂相比,部分阿片类药物在镇痛和改善躯体功能上优于其他药物,但仅限于中等确定性证据支持的合并效应估计时,阿片类药物间无差异。所有阿片类药物均增加胃肠道不良事件风险,但彼此间无危害差异。低至极低确定性证据提示缓释与即释阿片类药物在镇痛、躯体功能和胃肠道危害方面可能相似。

要点

  • 中等确定性证据下,不同阿片类药物在镇痛和躯体功能上无差异。
  • 所有阿片类药物均增加胃肠道不良事件风险,但彼此间无危害差异。
  • 低确定性证据提示缓释与即释阿片类药物的获益和胃肠道危害相似。

核心结论

  • 研究结果支持将不同种类和剂型的阿片类药物的效应估计合并,以指导慢性非癌痛的有效性评价。

研究设计与样本

  • 系统综述与随机对照试验的网络荟萃分析,检索MEDLINE、EMBASE、CINAHL和Cochrane Central Register of Controlled Trials至2021年3月。
  • 采用GRADE方法评估证据确定性。

主要发现

  • 与安慰剂相比,部分阿片类药物在镇痛和改善躯体功能上优于其他药物。
  • 仅限于中等确定性证据支持的合并效应估计时,阿片类药物间无差异。
  • 在中等确定性证据的阿片类药物中,所有药物均增加胃肠道不良事件风险,但无阿片类药物比其他更危险。
  • 低至极低确定性证据提示缓释与即释阿片类药物在镇痛、躯体功能和胃肠道危害方面可能相似。

临床怎么用

  • 临床可考虑将不同种类和剂型的阿片类药物效应估计合并用于慢性非癌痛的有效性评价。
  • 使用阿片类药物时需关注胃肠道不良事件风险。

局限性

  • 部分比较的证据确定性为低至极低,限制结论可靠性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Most systematic reviews of opioids for chronic pain have pooled treatment effects across individual opioids under the assumption they provide similar benefits and harms. We examined the comparative effects of individual opioids for chronic non-cancer pain through a network meta-analysis of randomised controlled trials. METHODS: We searched MEDLINE, EMBASE, CINAHL, and the Cochrane Central Register of Controlled Trials to March 2021 for studies that enrolled patients with chronic non-cancer pain, randomised them to receive different opioids, or opioids vs placebo, and followed them for at least 4 weeks. Certainty of evidence was evaluated using the GRADE approach. RESULTS: We identified 82 eligible trials (22 619 participants) that evaluated 14 opioids. Compared with placebo, several opioids showed superiority to others for analgesia and improvement in physical function; however, when restricted to pooled-effect estimates supported by moderate certainty evidence, no differences between opioids were evident. Among opioids with moderate certainty evidence, all increased the risk of gastrointestinal adverse events compared with placebo, although no opioids were more harmful than others. Low to very low certainty evidence suggests that extended-release vs immediate-release opioids may provide similar benefits for pain relief and physical functioning, and gastrointestinal harms. CONCLUSIONS: Our findings support the pooling of effect estimates across different types and formulations of opioids to inform effectiveness for chronic non-cancer pain.

来源:Br J Anaesth,查看原文。版权归原作者所有。

引用

  1. Noori A, Sadeghirad B, Wang L, et al. Comparative benefits and harms of individual opioids for chronic non-cancer pain: a systematic review and network meta-analysis of randomised trials. Br J Anaesth. 2022. PMID: 35817616. doi:10.1016/j.bja.2022.05.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。